治疗阿尔茨海默氏症的最新治疗方法:综合性审查
Radhakrishna Reddi Sree1, Manjunath Kalyan1,2, Nikhilesh Anand3
1Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.
ACS omega
|February 24, 2025
概括
阿尔茨海默病 (AD) 涉及粉样斑块和团. 目前的治疗方法可以控制症状,但新的疗法旨在通过向潜在病理来改变疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种不可逆转的,与年龄相关的神经退行性疾病.
- 关键的病理特征包括细胞外粉样β (Aβ) 斑块和细胞内神经纤维状团 (NFTs),由高化团组成.
- 遗传因素,如PSEN1,PSEN2,APOE4,APP和TAU基因的突变,都与此有关,尽管确切的原因尚不清楚.
研究的目的:
- 为了审查阿尔茨海默病的病理生理学.
- 探索目前正在研究的新型治疗点和疾病修饰治疗方法.
- 突出目前症状治疗方法的局限性.
主要方法:
- 对有关阿尔茨海默病病因,病原和治疗策略的现有文献的综述.
- 分析提出的假设,包括粉样蛋白积累,陶病,炎症,氧化应激和肠道失调.
- 检查临床试验中的或正在调查中的新兴治疗方法.
主要成果:
- 目前批准的治疗方法 (胆酶抑制剂和NMDA对抗剂) 仅提供症状缓解.
- 许多假设试图解释AD的病变发生,包括粉样蛋白级联,病,炎症和线粒体功能障碍.
- 正在探索一系列新的治疗策略,包括免疫疗法,分泌酶调节器,天然产品和再生方法.
结论:
- 现有的阿尔茨海默病疗法无法阻止或逆转疾病的进展.
- 专注于改变疾病机制的新兴治疗方法,如Aβ清除,陶聚合抑制和神经保护,显示出有前途.
- 对新型治疗点的进一步研究对于开发有效的阿尔茨海默氏症疾病修饰干预措施至关重要.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.6K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
相关概念视频
01:22Alzheimer's Disease: Treatment
149
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
149
01:26Alzheimer's Disease: Overview
425
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
425
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:24Treatment Strategies for Psychological Disorders
83
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
83
01:24Parkinson's Disease: Treatment
185
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
185
01:28Drug Therapy
34
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
34